Sciele Pharma, Inc. (SCRX) Announces That Plethora Solutions Holdings Has Completed European Phase III Trial of PSD502 for Premature Ejaculation  
10/1/2008 9:14:11 AM

ATLANTA--(BUSINESS WIRE)--Sciele Pharma, Inc. (“Sciele”) (NASDAQ:SCRX), a specialty pharmaceutical company, today announced that Plethora Solutions Holdings PLC (“Plethora”) (AIM:PLE), the specialist developer of products for the treatment and management of urological disorders, has completed its European Phase III study of PSD502 for the treatment of premature ejaculation (PE) in Europe. The study was initiated in December 2007 and these results from the blinded study are expected in the fourth quarter of 2008.